The treatment of wet AMD in Canada: Access to therapy (policy review)

Alan Cruess, David Maberley, David Wong, John Chen

Résultat de recherche: Articleexamen par les pairs

5 Citations (Scopus)

Résumé

Age-related macular degeneration (AMD) is the leading cause of blindness in North America, affecting 2 million Canadians older than age 50 years. AMD is subdivided into 2 types: an atrophic form, so-called "dry" AMD, and an exudative or "wet" form, characterized by the presence of choroidal neovascularization (CNV). Since 2000, after decades with no effective therapy aside from thermal obliterative laser treatment of CNV, 3 new treatments have been approved, each offering significant therapeutic advances at increasingly higher prices, and in an increasingly cost-containment-oriented payer environment. Many of Canada's public drug plans have been relatively slow to fund evidence-based, approved treatments. This paper reviews the disease, as well as the current private and public coverage for wet AMD treatments.

Langue d'origineEnglish
Pages (de-à)548-556
Nombre de pages9
JournalCanadian Journal of Ophthalmology
Volume44
Numéro de publication5
DOI
Statut de publicationPublished - oct. 2009

ASJC Scopus Subject Areas

  • Ophthalmology

PubMed: MeSH publication types

  • Journal Article
  • Review

Empreinte numérique

Plonger dans les sujets de recherche 'The treatment of wet AMD in Canada: Access to therapy (policy review)'. Ensemble, ils forment une empreinte numérique unique.

Citer